Oncotarget

Clinical Research Papers:

Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer

Su-xia Han, Xia Zhou, Xin Sui, Chen-chen He, Meng-jiao Cai, Jin-lu Ma, Yuan-yuan Zhang, Cong-ya Zhou, Chen-xian Ma, Armando Varela-Ramirez and Qing Zhu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:19907-19917. https://doi.org/10.18632/oncotarget.4529

Metrics: PDF 1968 views  |   HTML 1998 views  |   ?  


Abstract

Su-xia Han1,*, Xia Zhou2,*, Xin Sui1,*, Chen-chen He1, Meng-jiao Cai1, Jin-lu Ma1, Yuan-yuan Zhang1, Cong-ya Zhou1, Chen-xian Ma1, Armando Varela-Ramirez3 and Qing Zhu1

1 Department of Oncology, The First Affiliated Hospital of Xi’an Jiaotong University Medical College, Xi’an, Shaanxi, PR China

2 Department of Biotherapy, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China

3 Department of Biological Sciences and Border Biomedical Research Center, The University of Texas at El Paso, El Paso, Texas, USA

* This authors have contributed equally to this work

Correspondence to:

Qing Zhu, email:

Keywords: pancreatic cancer (PC), dickkopf-1 (DKK1), serum biomarker, diagnosis, prognosis

Received: April 14, 2015 Accepted: May 20, 2015 Published: June 19, 2015

Abstract

Purpose: To identify whether Dickkopf-1 (DKK1) could be a potential biomarker for early detection and prognosis in patients with pancreatic cancer (PC).

Methods: Serum was collected from 140 patients with pancreatic adenocarcinoma and 92 control patients without pancreatic adenocarcinoma. Serological levels of DKK1 were examined by enzyme-linked immunosorbent assay (ELISA). The sensitivity and specificity was compared with carbohydrate antigen 19-9 (CA19-9). A 2-year follow-up was monitored to evaluate the correlation between DKK1 serum levels and overall survival. The expression of DKK1 in PC tumor tissues was also evaluated using immunohistochemistry staining.

Results: Serum levels of DKK1 and CA19-9 were elevated in PC patients in the early-stage cases. These levels increased with the advancement of clinical stage. There was significant difference in DKK1 serum levels between early and advanced PC stages. Receiver operating characteristic curve (ROCC) analysis showed that DKK1 was significantly better than CA19-9 in differentiating patients with PC from the controls (area under the curve (AUC) 0.919 versus 0.853, respectively), especially in distinguishing early-stage cancer from chronic pancreatitis (CP). The expression of DKK1 in PC tissues correlated with its expression in serum samples. The overall survival rate was 24.4% in the group with higher DKK1 levels and was found to be significantly different from the group with lower DKK1 levels (33.3%).

Conclusion: DKK1 may be a novel diagnostic/prognostic biomarker for PC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 4529